[ad_1]
Around the world, it has had an extremely damaging effect that many countries have made decisions on shutdowns, shutdowns, arrests to slow the spread of the coronavirus, according to an official at the World Health Organization. The WHO has also been embroiled in controversy with the manufacturer of remdesivir, considered one of the most promising drugs for the coronavirus.
We do not support the plethora of restrictions and shutdowns as the primary means of defense against the virus, and we also draw the attention of world leaders to this, said David Nabarro, WHO envoy for coronaviruses, according to the Index.
Nabarro added that according to the WHO, closures are only justified if managers want to buy time to reorganize, rebalance resources, protect exhausted healthcare workers, otherwise not.
The WHO commissioner noted that the numerous restrictions had a devastating effect on society, the economy, as a result of which poverty, hunger, unemployment, which has a significant impact on tourism, hit its head.
Furthermore, people are not only affected economically by restrictions due to the epidemic. The stress and anxiety due to confinement have at least as serious consequences. In the United States, there has been an increase in domestic violence, an increase in drug overdoses, and an increased risk of suicide in children.
According to a WHO report on Thursday, their research showed that remdesivir had little or no effect on the duration and mortality of hospitalization of respiratory patients with Covid-19 during the 28-day study period.
This drug is considered one of the most promising treatments and Richter has recently started manufacturing it in Hungary.
The manufacturer Gilead has now questioned the results of the WHO investigation.
The US company told Reuters it thought the WHO research data was “contradictory, rushed” and that previous research had already confirmed the drug’s benefits, writes MTI.
According to Gilead, studies with remdesivir have shown that treatment reduces the time it takes to recover from Covid-19.
[ad_2]
